|Bid||0.0000 x 800|
|Ask||0.0000 x 800|
|Day's Range||0.7622 - 0.7950|
|52 Week Range||0.6000 - 3.2500|
|Beta (3Y Monthly)||2.12|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Daré, which focuses on women's health, said Monday that its BV1 — a thermosetting hydrogel containing clindamycin phosphate 2% — has been given the Qualified Infectious Disease Product, or QIDP, designation by the FDA for the treatment of bacterial vaginosis in women. The clinical cure rates for currently approved products in bacterial vaginosis are about 37-39%, and the condition affects over 21 million among women ages 14-49, according to Daré.
It's easy to match the overall market return by buying an index fund. Active investors aim to buy stocks that vastly...
R&D expense, including license fees, was $1.8M, compared to $1.2M and $1.9M in the prior-year and three-month periods, respectively. We note that Q1 expenses included $113k accrual associated with the license fees related to DARE-BV1, DARE’s new bacterial vaginosis candidate. The year-earlier period did not include any license-related expenses while the quarter-earlier period did include $275k in license fees.
By Brian Marckx, CFA NASDAQ:DARE READ THE FULL DARE RESEARCH REPORT Q4 / Pipeline Update Daré Bioscience (NASDAQ:DARE) reported financial results for their fourth quarter and provided an operational update. ...
The big shareholder groups in Daré Bioscience, Inc. (NASDAQ:DARE) have power over the company. Generally speaking, as a company grows, institutions will increase their ownership. Conversely, insiders often decrease their Read More...
Dare Bioscience (DARE) is showing no signs of slowing down as it relates to expanding their women’s health focused pipeline and their potential eventual related commercialization opportunities. Hammock Pharmaceuticals, Inc., TriLogic Pharma LLC and MilanaPharm LLC. DARE is also required to pay potential future milestones based on “clinical, regulatory, commercial launch and sales events”, and is also subject to paying royalties on any eventual sales. Bacterial Vaginosis, What It Is, How Prevalent and How Is it Treated?
By Brian Marckx, CFA NASDAQ:DARE READ THE FULL DARE RESEARCH REPORT Q3 / Pipeline Update Daré (NASDAQ:DARE) reported financial results for their third quarter and provided an operational update. Relative ...
Daré (DARE) continues to not only move their various development programs forward, but also continues to add promising candidates to their high-potential women’s health-focused pipeline. Relative to the latter, DARE’s most recent pipeline addition, CatSper, a potential first-in-kind contraceptive for both men and women, was announced in mid-July.